# Aflibercept in Treating Patients With Myelodysplastic Syndromes

> **NCT00509249** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Chronic Myelomonocytic Leukemia
- de Novo Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Previously Treated Myelodysplastic Syndromes
- Secondary Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** ziv-aflibercept
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00509249
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Early termination for discouraging results
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509249, "Aflibercept in Treating Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT00509249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*